Viridian Therapeutics, Inc.
VRDN
$19.23
$1.216.69%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -54.99% | -79.04% | -19.24% | -60.91% | -18.03% |
| Total Depreciation and Amortization | -20.42% | -19.31% | -93.43% | 26.53% | 7.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 22.43% | -1.66% | -74.19% | -57.71% | -46.82% |
| Change in Net Operating Assets | 42.57% | -179.45% | -91.81% | 172.69% | 337.02% |
| Cash from Operations | -63.65% | -104.88% | -92.98% | -73.68% | -1.87% |
| Capital Expenditure | 59.62% | -- | -137.50% | 27.48% | 68.58% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 22.04% | 170.01% | 62.98% | -274.16% | 51.25% |
| Cash from Investing | 22.17% | 169.95% | 62.93% | -276.24% | 52.23% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 263.81% | -94.98% | -72.62% | 24,119.88% | -93.16% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 98.01% | 88.90% | -2,848.05% | -- |
| Cash from Financing | 607.41% | -94.80% | -82.14% | 1,485.19% | -96.48% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -93.08% | 248.59% | -1,048.49% | 277.93% | 1,218.35% |